From the INTERNATIONAL SEARCHING AUTHORITY

То:
TOWNSEND AND TOWNSEND AND CREW LLP
Attn. Fang, Carol A.
Two Embarcadero Center
8th Floor
San Francisco, CA 94111
UNITED STATES OF AMERICA

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION

(PCT Rule 44.1)

015280-478100PC

Date of mailing (day/month/year)

07/01/2005

Applicant's or agent's file reference FOR FURTHER ACTION See paragraphs 1 and 4 below 15280-4781PC International application No. International filing date (day/month/year) PCT/US2004/014306 06/05/2004 / Applicant

1. 🔻	The applicant is hereby notified that the international search report and the written opinion of the International Se	earchine

Authority have been established and are transmitted herewith. Filing of amendments and statement under Article 19:

THE GOVERNMENT OF THE UNITED STATES, AS .

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

International Bureau of WIPO, 34 chemin des Colombettes Where? Directly to the 1211 Geneva 20, Switzerland, Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl

Stefanie Büchler

Authorized officer

Form PCT/ISA/220 (January 2004)

Fax: (+31-70) 340-3016

Willer open me'al (See notes on accompanying sheet)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

Notes to Form PCT/ISA/220 (first sheet) (January 1994)

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]:
 "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- [Where various kinds of amendments are made]:
 "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

it must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

Notes to Form PCT/ISA/220 (second sheet) (January 1994)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
15280-4781PC	ACTION as we	ll as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US2004/014306	06/05/2004	06/05/2003
Applicant		
THE GOVERNMENT OF THE UNI	TED STATES, AS	
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searching Au ansmitted to the International Bureau.	thority and is transmitted to the applicant
This International Search Report consists	of a total of sheets.	
X It is also accompanied by	a copy of each prior art document cited in this	s report.
Basis of the report a. With regard to the language, the language in which it was filed, unlined.	international search was carried out on the baless otherwise indicated under this item.	sis of the international application in the
The international this Authority (Ru	search was carried out on the basis of a transile 23.1(b)).	lation of the international application furnished to
b. X With regard to any nucle	otide and/or amino acid sequence disclosed	I in the international application, see Box No. I.
2. X Certain claims were fou	nd unsearchable (See Box II).	
3. Unity of invention is lac	king (see Box III).	
4. With regard to the title,		
X the text is approved as su	bmitted by the applicant.	·
the text has been establis	thed by this Authority to read as follows:	
	•	
5. With regard to the abstract,		
X the text is approved as su	* ''	
the text has been establis may, within one month fro	hed, according to Rule 38.2(b), by this Author on the date of mailing of this international sear	ity as it appears in Box No. IV. The applicant ch report, submit comments to this Authority.
6. With regards to the drawings ,		
	ublished with the abstract is Figure No. 1	
X as suggested by t		
	s Authority, because the applicant falled to su	•
	s Authority, because this figure better characte	erizes the invention.
b none of the figures is to be	e published with the abstract.	

International application No.

PCT/US2004/014306

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ntion, the international search was carried out on the basis of:
	a.	type of material X a sequence listing table(s) related to the sequence listing
	b.	format of material X in written format X in computer readable form
	C.	contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purpose of search
2.	х	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addit	tional comments:

International Application No PCT/US2004/014306

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/34 C12N15/62 A61P35/00 A61P35/02 A61K38/19 C07K14/535 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) $IPC \ 7 \ C12N \ C07K$

C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
	LIU S ET AL: "Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 21, 25 May 2001 (2001-05-25), pages 17976-17984, XP002974279 ISSN: 0021-9258 cited in the application the whole document	1-49

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 28 December 2004	Date of mailing of the international search report $07/01/2005$
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Sommerfeld, T

3

International Application No
PCT/US2004/014306

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	The state of the s	Tootan o omining.
Y	LIU SHIHUI ET AL: "Tumor cell-selective cytotoxicity of matrix metalloproteinase-activa ted anthrax toxin" CANCER RESEARCH, vol. 60, no. 21, 1 November 2000 (2000-11-01), pages 6061-6067, XP002311242 ISSN: 0008-5472 cited in the application the whole document	1-49
Y	FRANKEL ARTHUR E ET AL: "Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. MAY 2002, vol. 8, no. 5, May 2002 (2002-05), pages 1004-1013, XP002311243 ISSN: 1078-0432 cited in the application the whole document	1-49
Y	BLACK J H ET AL: "Diphtheria toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice." LEUKEMIA (BASINGSTOKE), vol. 17, no. 1, January 2003 (2003-01), pages 155-159, XP009041771 ISSN: 0887-6924 cited in the application the whole document	1-49
Υ	US 5 677 274 A (ARORA NAVEEN ET AL) 14 October 1997 (1997-10-14) column 10, line 28 - line 51	1-49
Y	WO 01/21656 A (HANSEN BIRKEDAL HENNING; NETZEL ARNETT SARAH (US); LIU SHI HUI (US);) 29 March 2001 (2001-03-29) cited in the application the whole document	1-49
A	KREITMAN R J: "IMMUNOTOXINS IN CANCER THERAPY" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD. LONDON, GB, vol. 11, no. 5, October 1999 (1999-10), pages 570-578, XP001012909 ISSN: 0952-7915	
	-/	

3

International Application No
PCT/US2004/014306

C.(Continua	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT		
ategory °	Citation of document, with indication, where appropriate, of the relevant passages	R	elevant to claim No.
	ABI-HABIB RALPH J ET AL: "A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts." BLOOD. 1 OCT 2004, vol. 104, no. 7, 1 October 2004 (2004-10-01), pages 2143-2148, XP002311244 ISSN: 0006-4971		

3

International application No. PCT/US2004/014306

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 24-48 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
No protest accompanied the payment of additional search fees.

Information on patent family members

International Application No
PCT/US2004/014306

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5677274	A	14-10-1997	US	5591631 A	07-01-1997
			ΑT	169959 T	15-09-1998
			AU	682500 B2	09-10-1997
			AU	6392294 A	29-08-1994
			CA	2155514 A1	18-08-1994
			DE	69412593 D1	24-09-1998
			DE	69412593 T2	18-02-1999
			EP	0684997 A1	06-12-1995
			ES	2122257 T3	16-12-1998
			WO	9418332 A2	18-08-1994
WO 0121656	Α	29-03-2001	AT	283280 T	 15-12-2004
			ΑÜ	771632 B2	01-04-2004
			AU	2572501 A	24-04-2001
			CA	2385122 A1	29-03-2001
		•	EP	1214340 A2	19-06-2002
			WO	0121656 A2	29-03-2001

Form PCT/ISA/210 (patent family annex) (January 2004)